Zymeworks to Present on Clinical and Preclinical Programs at Multiple Upcoming Medical Conferences

Zymeworks is pleased to announce new and updated clinical and preclinical data presentations at the following medical conferences.

14th Annual World Bispecific Summit
October 2-4, 2023
Boston, MA

Dr. Nina Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks will lead a seminar on Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors at 1:30 pm Eastern Time (ET). The presentation will provide an overview of antibody engineering strategies and a review of trispecific t-cell engagers mechanism of action with comparisons to T cell engaging bispecifics and combinations.

October 11-15, 2023
Boston, Massachusetts

Dr. Raffaele Columbo, Principal Scientist & Group Lead, Medicinal Chemistry at Zymeworks, will present “Refining our understanding of ADCs: Drug development insights from 40 years of data in Plenary Session 2: The Journey of Antibody Drug Conjugate Development on Thursday, October 12 at 10:00 am ET on Level 3, Ballroom AB of the Hynes Convention Center.

Zymeworks will present clinical data for zanidatamab zovodotin in a poster titled Phase 1 Study of Zanidatamab Zovodotin (ZW49): Safety Profile and Recommended Dose (RD) in Patients with Human Epidermal Growth Factor 2 (HER2)-positive Solid Cancers (Poster #: B130) in Poster Session B on Friday, October 13, 2023 at 12:30 – 4:00 pm ET in Exhibit Hall D, Level 2 of the Hynes Convention Center.

European Society of Medical Oncology (ESMO)
October 20-26, 2023
Madrid, Spain

In partnership with Zymeworks’ zanidatamab collaboration partners, Jazz Pharmaceuticals Ltd. and BeiGene, Ltd., Zymeworks will present updated results from the Phase 1b/2 study of zanidatamab plus chemotherapy and tislelizumab as first-line therapy for patients with advanced HER2-postive gastric/gastroesophageal junction adenocarcinoma in a poster presentation. Additionally, quality of life outcomes from the Phase 2b HERIZON-BTC-01 study evaluating patients with zanidatamab-treated HER2-positive biliary tract cancer will be presented in a poster presentation. More information will be available on Monday, October 16, when abstracts are published on the ESMO website.

14th Annual World ADC San Diego
October 16-19, 2023
San Diego, CA

Dr. Laurence Madera, Senior Scientist at Zymeworks, will present “ZW251 – A novel glypican-3 targeting ADC bearing a topoisomerase I inhibitor payload” in the Translational Session on Tuesday, October 17 at 11:30 am Pacific Time (PT).

Andrea Hernandez, Scientist at Zymeworks, will present “ZW220 – A potential first-in-class TOPO1i ADC for the treatment of NaPi2b-expressing solid tumors” in the Translational Session on Wednesday, October 18 at 12:30 pm PT.

Society for Immunotherapy of Cancer (SITC)
November 1-5, 2023
San Diego, CA

Zymeworks will present two abstracts on our tri-specific t-cell engager (TriTCE) programs in poster presentations at the SITC Conference:

Title: TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the therapeutic window for treatment of poorly infiltrated tumors.
Abstract Number: 1372
Date and Time: Saturday, November 4, 2023 at 9:00 am – 8:30 pm PT
Location: Exhibit Halls A and B1, San Diego Convention Center

Title: TriTCE CPI: a novel trispecifc T cell engager platform with integrated PD-1/PD-L1 checkpoint inhibition engineered for the treatment of immunosuppressed tumors
Abstract Number: 1396
Date and Time: Saturday, November 4, 2023 at 9:00 am – 8:30 pm PT
Location: Exhibit Halls A and B1, San Diego Convention Center


All presentations will be available to conference registrants on the conference website as well as to the general public at www.zymeworks.com/publications at the time of presentation at the conference.